Solid Tumors
Select Clinical Trial
Protocol Number: Mirati Krystal MRTX849
Protocol Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Eligibility: Men or women, ages 18 and older, diagnosed with advanced cancer, which has a KRAS G12C mutation.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: EAY131/MATCH
Protocol Title: Molecular Analysis for Therapy Choice (MATCH)
Eligibility: Men or women, ages 18 and older whose cancer has not responded to conventional treatment or whose cancer does not have a known effective treatment. Patients/treating physician must have received notification of actionable mutation of interest(aMOI) following genetic testing of tumor at an accepted outside laboratory such as Foundation One, Caris, etc.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Seattle Genetics SGNLVA-005; NCT04032704
Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Eligibility: Men and women age 18 and older diagnosed with metastatic lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, gastric, gastroesophageal junction (GEJ) adenocarcinoma, Castrate Resistant Prostate cancer, or Melanoma who have progressed following their first line of therapy.
Contact Information: (910) 715-2200